Neuphoria Therapeutics Inc. (NEUP)
| Market Cap | 25.71M +182.5% |
| Revenue (ttm) | -13,267 |
| Net Income | -17.43M |
| EPS | -4.95 |
| Shares Out | 5.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 174,444 |
| Open | 4.770 |
| Previous Close | 4.720 |
| Day's Range | 4.410 - 4.780 |
| 52-Week Range | 3.645 - 21.400 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 7.00 (+46.75%) |
| Earnings Date | May 15, 2026 |
About NEUP
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for th... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NEUP stock is "Hold" and the 12-month stock price target is $7.0.
News
Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with no price target after the company announced that the Phase 3 AFFIRM-1 trial of BNC210 for…
Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees
Neuphoria Therapeutics (NEUP) announced that Institutional Shareholders Services, ISS, a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on t...
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) ...
Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neuphoria Therapeutics (NEUP) to $7 from $21 and keeps a Buy rating on the shares. The firm says the company is “caught…
Neuphoria Therapeutics responds to Lynx1’s revised indication of interest
Neuphoria Therapeutics (NEUP) issued the following statement in response to dissident stockholder, Lynx1 Master Fund’s, revised indication of interest to acquire the Company. As previously announced, ...
Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria's Nominees on the WHITE Prox...
Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1
The company states: “Neuphoria Therapeutics (NEUP) issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP full of deception and distraction...
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies...
Neuphoria Therapeutics urges stockholders to vote for company nominees
Neuphoria Therapeutics (NEUP) issued a letter to its stockholders regarding Neuphoria’s 2025 Annual Meeting of Stockholders, which is scheduled to be held on December 12, 2025. The company said, “The…
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLO...
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) ...
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments f...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Neuphoria (NEUP), 543% surge in interest Fusemachines (FU...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: iBio (IBIO), 1,405% surge in interest Neuphoria Therapeut...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: iBio (IBIO), 1,833% surge in interest Neuphoria Therapeut...
Why Is Neuphoria Therapeutics Stock (NEUP) Down 65% Today?
Neuphoria Therapeutics stock fell hard on Tuesday after the company posted results from a Phase 3 clinical trial.
Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital
Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210…
Neuphoria Therapeutics Inc trading resumes
17:00 EDT Neuphoria Therapeutics (NEUP) Inc trading resumes
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program
Neuphoria Therapeutics (NEUP) announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder did not meet its primary endpoint of change from baseline…
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neupho...
Neuphoria Therapeutics Inc trading halted, news pending
16:10 EDT Neuphoria Therapeutics (NEUP) Inc trading halted, news pending
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025
Neuphoria Therapeutics price target raised to $35 from $18 at Maxim
Maxim raised the firm’s price target on Neuphoria Therapeutics (NEUP) to $35 from $18 and keeps a Buy rating on the shares. The firm cites the company’s announcement that enrollment…
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments ...
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments f...